Evaluation of Stability and Sterility of Extended Use of Single-use, Preservative-free 0.0015% Tafluprost Eye Drops: An In Vivo Study.

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210224008

Enrollment

Registered

2021-02-24

Start date

2021-03-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma patients Glaucoma

Interventions

One single-use units of preservative-free 0.0015% Tafluprost eye drops for 2 days (24 hours).,One single-use units of preservative-free 0.0015% Tafluprost eye drops for 1 day (single use).

Experimental Drug,No Intervention Drug

Tafluprost 2 days,Tafluprost 1 day

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. > 18 years olds 2. Current use of PGAs eye drop 3. Well-controlled IOP with PGAs eye drop 4. Regular follow-up visit

Exclusion criteria

Exclusion criteria: 1. History of allergy or adverse reaction from PGAs 2. Post trabeculectomy patients 3. Previous ocular surgery within 3 months 4. History of corneal or conjunctival infection 5. Pregnancy and lactation period women

Design outcomes

Primary

Measure	Time frame
Intraocular pressure Follow up visit (3 months and 6 months) Goldmann applanation tonometry	—

Secondary

Measure	Time frame
Corneal or conjunctival infection Every visit Slit lamp examination	—

Countries

Thailand

Contacts

Public ContactVisanee Tantisevi

Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University

tvisanee@gmail.com66818365738

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026